LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article: Clinical results and mechanism of action of icosapent ethyl.

    Borghi, Claudio / Bragagni, Alessio

    European heart journal supplements : journal of the European Society of Cardiology

    2023  Volume 25, Issue Suppl B, Page(s) B37–B40

    Abstract: Serum triglyceride concentration is considered as an additional component that often contributes to residual cardiovascular risk in patients already at high risk; these considerations have led to several clinical studies aimed at evaluating the efficacy ... ...

    Abstract Serum triglyceride concentration is considered as an additional component that often contributes to residual cardiovascular risk in patients already at high risk; these considerations have led to several clinical studies aimed at evaluating the efficacy of supplements based on omega-3 fatty acids in reducing serum triglyceride levels and consequently cardiovascular risk. Although partially inconclusive and contradictory, these clinical trials laid the foundations for the implementation of the REDUCE-IT and EVAPORATE studies, in which the use of a purified derivative of eicosapentaenoic acid, icosapent ethyl, resulted in a significant reduction both of the composite for cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke and of the reduction in the volumetric progression up to the induction of a real regression of the coronary atheromatous plaques detected by computerized coronary angiography tomography. Surprisingly, these brilliant results seem to be, at least in part, not related to the reduction of triglyceride concentration. The purpose of this article is to examine the latest evidence regarding icosapent ethyl therapy, describing the results of the main clinical trials performed to date and formulating hypotheses on the potential mechanisms of action of this fascinating molecule.
    Language English
    Publishing date 2023-04-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 1463769-8
    ISSN 1554-2815 ; 1520-765X
    ISSN (online) 1554-2815
    ISSN 1520-765X
    DOI 10.1093/eurheartjsupp/suad088
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1563 -Suppl.-: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: 'Use of lipid-lowering therapy: the guidelines, the drugs or the patient?'

    Borghi, Claudio / Bragagni, Alessio

    European heart journal supplements : journal of the European Society of Cardiology

    2022  Volume 24, Issue Suppl I, Page(s) I29–I33

    Abstract: The current step up approach in the therapy of dyslipidemias aims to reduce the amount of LDL cholesterol below a threshold that varies according to the patient's risk category, with a pharmacological approach that sees statins as a fundamental ... ...

    Abstract The current step up approach in the therapy of dyslipidemias aims to reduce the amount of LDL cholesterol below a threshold that varies according to the patient's risk category, with a pharmacological approach that sees statins as a fundamental cornerstone. Although absolutely functional in reducing cardiovascular events, this therapeutic algorithm does not yet take into consideration the innumerable phenotypic variables that we can find in dyslipidemic subjects. The ever finer understanding of the pathophysiological mechanisms underlying dyslipidemias in combination with the novelties obtained through DNA genotyping will allow, in the near future, the development of a 'tailor-made' therapy for each category of patients. This article will summarize the most recent evidence regarding the therapy of dyslipidemias, with particular attention to the concept of cumulative exposure and some hypotheses on possible initial therapeutic proposals in patients with diabetes, vasculopathy, with hypertriglyceridaemia and with high levels of Lp (a).
    Language English
    Publishing date 2022-11-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 1463769-8
    ISSN 1554-2815 ; 1520-765X
    ISSN (online) 1554-2815
    ISSN 1520-765X
    DOI 10.1093/eurheartjsupp/suac069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1563 -Suppl.-: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Caffè, ipertensione e malattie cardiovascolari: nuove acquisizioni.

    Borghi, Claudio / Bragagni, Alessio

    Giornale italiano di cardiologia (2006)

    2022  Volume 23, Issue 5, Page(s) 323–327

    Abstract: Coffee is the most widespread drink in the world, immediately after water. In the United States, coffee consumption amounts to 400 million cups per day and is, globally, the main source of caffeine. In view of such a high worldwide use, it is of great ... ...

    Title translation New evidence on coffee consumption, hypertension and cardiovascular diseases.
    Abstract Coffee is the most widespread drink in the world, immediately after water. In the United States, coffee consumption amounts to 400 million cups per day and is, globally, the main source of caffeine. In view of such a high worldwide use, it is of great interest for the scientific community to understand whether or not this drink has an impact on health. In the first clinical studies aimed at investigating the effects of coffee, a possible deleterious effect on systemic blood pressure and on the incidence of cardiovascular diseases was hypothesized. These data have been interpreted on the basis of the mild increase in blood pressure that can occur immediately following the consumption of caffeine. Coffee, however, contains more than 1000 chemical components, among which are polyphenols such as chlorogenic acid and lignans, with antioxidant and anti-inflammatory properties, and substances with a vasodilating action such as vitamin E, niacin, potassium and magnesium. It is therefore likely that if, on the one hand, caffeine causes a mild increase in blood pressure, on the other hand, the countless substances contained in coffee are able to counteract this effect, actually resulting in a health benefit. The latest evidence available in the literature shows indeed how the consumption of 3-5 cups of coffee a day is not only harmless, but is even able to significantly reduce the incidence of and mortality from cardiovascular diseases, as well as mortality from all causes.
    MeSH term(s) Caffeine/adverse effects ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Chlorogenic Acid ; Coffee/chemistry ; Humans ; Hypertension/complications ; Hypertension/epidemiology
    Chemical Substances Coffee ; Chlorogenic Acid (318ADP12RI) ; Caffeine (3G6A5W338E)
    Language Italian
    Publishing date 2022-04-26
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2272414-X
    ISSN 1972-6481 ; 1827-6806
    ISSN (online) 1972-6481
    ISSN 1827-6806
    DOI 10.1714/3796.37814
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6738: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors.

    Borghi, Claudio / Bragagni, Alessio

    European heart journal supplements : journal of the European Society of Cardiology

    2020  Volume 22, Issue Suppl L, Page(s) L28–L32

    Abstract: Type 2 diabetes mellitus represents one of the most common chronic-degenerative diseases in modern society and is the cause of innumerable micro- and macrovascular complications that weigh on the national health system. Until a few years ago, there was ... ...

    Abstract Type 2 diabetes mellitus represents one of the most common chronic-degenerative diseases in modern society and is the cause of innumerable micro- and macrovascular complications that weigh on the national health system. Until a few years ago, there was no anti-diabetic drug that, in addition to lowering blood sugar, had an impact on cardiovascular risk in these patients. In this report, we will analyse the characteristics, contraindications, and evidence in favour of the use of two innovative categories of molecules that aim, for the first time in history, at controlling blood sugar levels and simultaneously lower cardiovascular risk in diabetics individuals: the glucagon-like peptide receptor agonists and the sodium-glucose cotransporter 2 inhibitors.
    Language English
    Publishing date 2020-11-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 1463769-8
    ISSN 1554-2815 ; 1520-765X
    ISSN (online) 1554-2815
    ISSN 1520-765X
    DOI 10.1093/eurheartj/suaa129
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1563 -Suppl.-: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes.

    Bragagni, Alessio / Piani, Federica / Borghi, Claudio

    European heart journal supplements : journal of the European Society of Cardiology

    2021  Volume 23, Issue Suppl E, Page(s) E40–E44

    Abstract: It is now well-established that the therapy of type II diabetes mellitus has undergone a radical change in the past 15 years: countless innovative drugs, such as SGLT2I, able to guarantee an optimization of glycaemic control without causing hypoglycaemia, ...

    Abstract It is now well-established that the therapy of type II diabetes mellitus has undergone a radical change in the past 15 years: countless innovative drugs, such as SGLT2I, able to guarantee an optimization of glycaemic control without causing hypoglycaemia, today represent real therapeutic cornerstones not only for the intrinsic ability of these molecules to ensure better glycaemic control but also for the effects they exert on the cardiovascular system. Several pioneering clinical trials, such as EMPA-REG, CANVAS, and DECLARE-TIMI-58, have demonstrated clear benefits of empagliflozin, canagliflozin, and dapagliflozin, respectively, in reducing cardiovascular risk and diabetes-associated macrovascular complications in the diabetic population. The promising results that emerged from these trials represent the spark that triggered a series of studies aimed at evaluating the efficacy of gliflozines in the treatment of patients with heart failure even in the absence of diabetes. Preliminary results confirm the efficacy of SGLT2I in the treatment of this population, representing a real therapeutic revolution.
    Language English
    Publishing date 2021-10-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 1463769-8
    ISSN 1554-2815 ; 1520-765X
    ISSN (online) 1554-2815
    ISSN 1520-765X
    DOI 10.1093/eurheartj/suab094
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1563 -Suppl.-: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia.

    Cicero, Arrigo F G / Fogacci, Federica / Bragagni, Alessio / Borghi, Claudio

    Internal and emergency medicine

    2022  Volume 18, Issue 1, Page(s) 307–310

    MeSH term(s) Humans ; Aged ; Homozygous Familial Hypercholesterolemia ; Antibodies, Monoclonal, Humanized/adverse effects ; Xanthomatosis/drug therapy ; Xanthomatosis/etiology ; Tendons
    Chemical Substances evolocumab (LKC0U3A8NJ) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2022-10-06
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2454173-4
    ISSN 1970-9366 ; 1828-0447
    ISSN (online) 1970-9366
    ISSN 1828-0447
    DOI 10.1007/s11739-022-03106-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6673: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Hyperuricemia and mortality in heart failure: Is it time to change the route?

    Borghi, Claudio / Cosentino, Eugenio / Bragagni, Alessio

    European journal of internal medicine

    2020  Volume 72, Page(s) 40–41

    MeSH term(s) Heart Failure ; Humans ; Hyperuricemia ; Prognosis ; Stroke Volume ; Uric Acid
    Chemical Substances Uric Acid (268B43MJ25)
    Language English
    Publishing date 2020-01-21
    Publishing country Netherlands
    Document type Journal Article ; Comment
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2020.01.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2608: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Not all that trembles…: a rare case of extrapyramidal impairment.

    Landolfo, Matteo / Bragagni, Alessio / Borghi, Claudio

    Internal and emergency medicine

    2019  Volume 16, Issue 3, Page(s) 729–733

    MeSH term(s) Aged, 80 and over ; Basal Ganglia Diseases/diagnosis ; Basal Ganglia Diseases/etiology ; Diagnosis, Differential ; Diagnostic Imaging ; Humans ; Liver Cirrhosis/complications ; Liver Cirrhosis/diagnosis ; Male
    Language English
    Publishing date 2019-12-18
    Publishing country Italy
    Document type Clinical Conference ; Journal Article
    ZDB-ID 2454173-4
    ISSN 1970-9366 ; 1828-0447
    ISSN (online) 1970-9366
    ISSN 1828-0447
    DOI 10.1007/s11739-019-02255-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6673: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients.

    Borghi, Claudio / Soldati, Mario / Bragagni, Alessio / Cicero, Arrigo F G

    Expert opinion on drug safety

    2020  Volume 19, Issue 12, Page(s) 1577–1583

    Abstract: Introduction: ACE-inhibitors (ACEI) and diuretics are the typical first-line antihypertensive drugs with complementary mechanisms of action. The present paper is summarizing the evidence supporting the efficacy of their combination in a broad range of ... ...

    Abstract Introduction: ACE-inhibitors (ACEI) and diuretics are the typical first-line antihypertensive drugs with complementary mechanisms of action. The present paper is summarizing the evidence supporting the efficacy of their combination in a broad range of hypertensive patients.
    Areas covered: This source of data is different trials investigating the use of ACEI and diuretics in different populations of patients. The available evidence supports some advantage for thiazide-type compounds (chlortalidone-CHT and indapamide-IND) in the prevention of major CV complications. In terms of safety, hydrochlorothiazide (HCTZ) and indapamide are associated with a lesser rate of hypokalemia and abnormalities of metabolic profile (glucose control, uric acid levels, serum potassium levels). As far as the results of clinical trials, the most relevant studies are involving the combination of benazepril or perindopril with HCTZ (benazepril) or IND (Perindopril) respectively. All these studies have resulted in a favorable clinical outcome. In terms of safety profile, the combination of ACEi and diuretic is safe and comparable with that of ACEi and calcium channel blockers with no differences in the rate of major adverse events (cough or angioedema) and a lower rate of ankle edema.
    Expert opinion: The combination of ACEi and diuretic is safe and well-tolerated and should be considered among the first-line treatments in most of the patients with hypertension.
    MeSH term(s) Angiotensin-Converting Enzyme Inhibitors/administration & dosage ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/adverse effects ; Diuretics/administration & dosage ; Diuretics/adverse effects ; Drug Therapy, Combination ; Humans ; Hypertension/drug therapy ; Thiazides/administration & dosage ; Thiazides/adverse effects
    Chemical Substances Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Diuretics ; Thiazides
    Language English
    Publishing date 2020-10-12
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2020.1836151
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6096: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top